Protein & Cell, 27 May, 2024, DOI：https://doi.org/10.1093/procel/pwae033

A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2

Zijing Jia, Kang Wang, Minxiang Xie, Jiajing Wu, Yaling Hu, Yunjiao Zhou, Ayijiang Yisimayi, Wangjun Fu, Lei Wang, Pan Liu, Kaiyue Fan, Ruihong Chen, Lin Wang, Jing Li, Yao Wang, Xiaoqin Ge, Qianqian Zhang, Jianbo Wu, Nan Wang, Wei Wu, Yidan Gao, Jingyun Miao, Yinan Jiang, Lili Qin, Ling Zhu, Weijin Huang, Yanjun Zhang, Huan Zhang, Baisheng Li, Qiang Gao, Xiaoliang Sunney Xie, Youchun Wang, Yunlong Cao, Qiao Wang, Xiangxi Wang

Abstract

The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has lasted for more than four years, resulting in an unprecedented global public health crisis. Progress in halting this pandemic seems slow due to the emergence of variants of concern, such as the B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma, also known as B.1.1.28.1), B.1.617.2 (Delta), and B.1.1.529 (Omicron), that appear to be high transmissible and more resistant to neutralizing antibodies (Wang et al., 2021g). New variants are thought to be responsible for re-infections (Hacisuleyman et al., 2021). A general decrease in immune protection against SARS-CoV-2 variants within 6–12 months after the primary infection or vaccination is also observed (Widge et al., 2021). However, not much is known about the immunogenic features of such a booster dose of a COVID-19 vaccine. In addition, there are large gaps in our understanding ofcorrelating immunogenic findings from surrogate endpoints to gauge vaccine efficacy.

Article link：https://academic.oup.com/proteincell/advance-article/doi/10.1093/procel/pwae033/7683113